Publications by authors named "Jan Hillson"

Claim this Profile
F
First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects.
Jing Yang, Jason D Lickliter, Jan L Hillson, Gary D Means, Russell J Sanderson

Clin Transl Sci· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial.
Peter A Merkel, David R Jayne, Chao Wang, Jan Hillson, Pirow Bekker

JMIR Res Protoc· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor.
Victor Farutin, Thomas Prod'homme, Kevin McConnell, Nathaniel Washburn, Patrick Halvey, Jan L Hillson

Arthritis Res Ther· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.
Leona E Ling, Jan L Hillson, Renger G Tiessen, Tjerk Bosje, Mattheus Paulus van Iersel

Clin Pharmacol Ther· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
Jan Hillson, Tim Mant, Molly Rosano, Carolyn Huntenburg, Mehrshid Alai-Safar

Pharmacol Res Perspect· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peginterferon Lambda-1a Is Associated with a Low Incidence of Autoimmune Thyroid Disease in Chronic Hepatitis C.
Paul Fredlund, Jan Hillson, Todd Gray, Lynn Shemanski, Dessislava Dimitrova

J Interferon Cytokine Res· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 2: Exposure-response analyses for efficacy and safety variables.
Matthew Hruska, Xiaodong Wang, Phyllis Chan, Alaa Ahmad, Jeremy Freeman, Jan Hillson

J Clin Pharmacol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates.
Xiaodong Wang, Matthew Hruska, Phyllis Chan, Alaa Ahmad, Jeremy Freeman, Jan Hillson

J Clin Pharmacol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.
Andrew J Muir, Sanjeev Arora, Gregory Everson, Robert Flisiak, Jacob George, Jan Hillson

J Hepatol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study.
Richard Furie, Kathy Nicholls, Tien-Tsai Cheng, Frederic Houssiau, Ruben Burgos-Vargas, Jan L Hillson

Arthritis Rheumatol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic.
Henrik Andersen, Jeff Meyer, Jeremy Freeman, Sean E Doyle, Kevin Klucher, Jan L Hillson

J Clin Transl Hepatol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials.
David Wofsy, Jan L Hillson, Betty Diamond

Arthritis Rheum· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions.
David Wofsy, Jan L Hillson, Betty Diamond

Arthritis Rheum· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.
Ellen M Ginzler, Stephen Wax, Anand Rajeswaran, Samuel Copt, Jan Hillson

Arthritis Res Ther· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis